Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.

Science (New York, N.Y.) - 19 Aug 2011

Li Fubin, Ravetch Jeffrey V

Abstract excerpt

CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, is expressed on antigen-presenting cells (APCs) and is essential for immune activation. Although agonistic CD40 antibodies have been developed for immunotherapy, their clinical efficacy has been limited. We have found that coengagement of the Fc domain of agonistic CD40 monoclonal antibodies (mAbs) with the inhibitory Fcγ receptor FcγRIIB is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antibody Affinity
Share to Antibody-Dependent Cell Cytotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigen-Presenting Cells

Share to CD40 Antigens

Share to Immunoglobulin Fc Fragments

Share to Lymphoma, B-Cell

Share to Ovalbumin

Source

Open in PubMed Open full text

Identifiers

PMID: 21852502
DOI: 10.1126/science.1206954
PMCID: PMC3164589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.PMID 21852502Read ↗

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.Semantic proximity Read ↗

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivoSemantic proximity Read ↗

Cell targeting and immunostimulatory properties of a novel Fcγ-receptor independent agonistic anti-CD40 antibody in rhesus macaquesSemantic proximity Read ↗

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector FunctionsSemantic proximity Read ↗

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.Semantic proximity Read ↗

FcγRIIB as a modulator of autoimmune disease susceptibilitySemantic proximity Read ↗

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Semantic proximity Read ↗

Tregs constrain CD8 <sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapySemantic proximity Read ↗

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.Semantic proximity Read ↗

Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentSemantic proximity Read ↗

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamilySemantic proximity Read ↗

Prospect of Targeting the CD40 Pathway for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.